VAISHALI PHARMA LIMITED Intrinsic Value

VAISHALI · Healthcare · Current price ₹8.04

Full stock page
DocStoX fair value
₹7
low confidence
Current price
₹8
Upside to fair value
-18.4%
Verdict
Expensive
Quality score
2.7 / 10
Model it yourself — Intrinsic Value Calculator
Opens pre-filled with VAISHALI PHARMA LIMITED's latest numbers.

Is VAISHALI PHARMA LIMITED undervalued?

DocStoX estimates the fair value of VAISHALI PHARMA LIMITED at ₹7 per share, versus the current market price of ₹8. That puts the stock about -18.4% above our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.

How this fair value is calculated

This estimate blends 3 independent methods: Residual income (₹5), Relative P/E (₹10), Graham floor (₹6). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.

Bear, base and bull scenarios

Our scenarios span ₹5 (bear) to ₹7 (base) to ₹10 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.

Margin of safety

Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹8 versus an intrinsic value of ₹7, VAISHALI PHARMA LIMITED currently offers -18.4% of negative margin (i.e. a premium).

More on VAISHALI PHARMA LIMITED

Fair ValueDCFValuationFinancial RatiosPeers

DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.